相关实验视频

Updated: Jul 9, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

菌酸莫菲提尔与连接组织疾病相关的间歇性肺病患者的循环胺相比:疗效和安全性分析

Pengfei Wang¹, Li Zhang², Qian Guo¹

¹Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, China.

Open medicine (Warsaw, Poland)

|November 29, 2023

概括

菌酸莫菲蒂尔 (MMF) 和环胺 (CYC) 均改善了结缔组织疾病相关的间歇性肺病 (CTD-ILD) 的肺功能. CYC显示出更大的FVC改善,但有更高的毒性,而MMF显示出更好的安全性和生存结果.

科学领域:

肺部医学肺部医学
类风湿病学类风湿病学
药理学药理学是指药理学的学科.

背景情况:

与连接组织疾病相关的间歇性肺病 (CTD-ILD) 提出了治疗挑战.
决定对CTD-ILD进行最终治疗需要仔细考虑疗效和安全性.

研究的目的:

为了比较mycophenolate mofetil (MMF) 与cyclophosphamide (CYC) 在治疗CTD-ILD中的疗效和安全性.
评估MMF和CYC对肺功能和患者存活率的影响.

主要方法:

一项涉及两组CTD-ILD患者的比较研究.
货币基金队列 (n=105) 接受0.5g两次治疗2年;CYC队列 (n=140) 每隔一天接受50mg (最大累积剂量为10g).
在治疗前和治疗后评估了肺功能测试 (%强迫生命能力[%FVC]和%一氧化碳扩散能力).

主要成果:

货币货币基金和CYC都显著改善了FVC和DLCO后处理的% (p < 0.001).
CYC队列在%FVC (p < 0.0001) 中表现出更大的改善,但患白血病,血小板减少,严重不良事件和死亡率更高 (p < 0.05).
与CYC相比,MMF显示出更高的安全性和患者存活率.

结论:

菌酸莫菲提尔和环胺都能改善CTD-ILD中的肺功能.
与CTD-ILD治疗中的环胺相比,mycophenolate mofetil提供了一种毒性较低的替代品,改善了患者的生存率.

关键词:

间歇性肺病间歇性肺病结合组织疾病结合组织疾病环酸胺的使用方法强迫生命能力强迫生命能力.基酸莫菲蒂尔是什么普雷迪尼索隆 (prednisolone) 是一种药物.

更多相关视频

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...